Risk of hyperglycaemia & diabetic ketoacidosis w/ inadequate dosing or discontinuation of treatment in patients w/ type 1 DM. Risk of hypoglycaemia w/ excessive insulin dose, omitted meal or unplanned, strenuous physical exercise. Change in usual warning symptoms of hypoglycaemia in patients w/ greatly improved blood glucose control eg, intensified therapy, & w/ longstanding diabetes. Concomitant illness, especially infections & feverish conditions; diseases in the kidney, liver, or affecting the adrenal, pituitary or thyroid gland. Transfer to another type or brand of insulin; change in strength, brand (manufacturer), type, origin (animal insulin, human insulin, insulin analogue) &/or method of manufacture (recombinant DNA vs. animal source insulin). Rotate inj site continuously to reduce or prevent inj site reactions. Patients w/ severe hypoalbuminaemia. Cases of CHF in combination w/ thiazolidinediones. May impair ability to drive & use machines. Pregnancy & lactation.